Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.5.2095

Fulvestrant 250mg versus Anastrozole 1 mg in the Treatment of Advanced Breast Cancer: a Meta-Analysis of Randomized Controlled Trials  

Gong, Dan-Dan (Institute of Molecular Biology and Translational Medicine, Affiliated People's Hospital, Jiangsu University)
Man, Chang-Feng (Institute of Molecular Biology and Translational Medicine, Affiliated People's Hospital, Jiangsu University)
Xu, Juan (Institute of Molecular Biology and Translational Medicine, Affiliated People's Hospital, Jiangsu University)
Fan, Yu (Institute of Molecular Biology and Translational Medicine, Affiliated People's Hospital, Jiangsu University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.5, 2014 , pp. 2095-2100 More about this Journal
Abstract
Objective: Most patients with advanced breast cancer experience resistance to endocrine treatment and eventual disease progression. This meta-analysis was designed to compare the efficacy and tolerability of fulvestrant 250mg with anastrozole 1mg in postmenopausal women with advanced breast cancer. Methods: Electronic literature databases (Cochrane Library, Medline, and Embase) were searched for randomized controlled trials (RCTs) published prior to August 2013. Only RCTs that compared fulvestrant 250mg to anastrozole 1mg in postmenopausal women with advanced breast cancer were selected. The main outcomes were time to treatment failure (TTF), time to progression (TTP), duration of response (DOR), clinical benefit rate, and tolerability. Results: Four RCTs covering 1,226 patients (fulvestrant, n=621; anastrozole, n=605) were included in the meta-analysis. Fulvestrant increased the DOR compared to anastrozole (HR =1.31, 95% confidence interval [CI] 1.13-1.51). There was no statistically significant difference between fulvestrant and anastrozole in terms of TTF (HR=1.02, 95%CI 0.89-1.17), complete response (RR=1.79, 95%CI, 0.93-3.43), and partial response (RR=0.91, 95%CI 0.69-1.21). As for safety, there was no statistical significance between the two groups for common adverse events. Conclusion: Fulvestrant 250mg is as effective and well-tolerated as anastrozole 1mg treatment for advanced breast cancer in postmenopausal women whose disease progressed after prior endocrine treatment. Thus, fulvestrant may serve as a reasonable alternative to anastrozole when resistance is experienced in breast cancer cases.
Keywords
Fulvestrant; anastrozole; advanced breast cancer; meta-analysis;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Robertson JF (2007). Fulvestrant (Faslodex) -- how to make a good drug better. Oncologist, 12, 774-84.   DOI   ScienceOn
2 Osborne CK, Pippen J, Jones SE, et al (2002). Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol, 20, 3386-95.   DOI   ScienceOn
3 Pritchard KI, Rolski J, Papai Z, et al (2010). Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat, 123, 453-61.   DOI
4 Robertson JF, Nicholson RI, Bundred NJ, et al (2001). Comparison of the short-term biological effects of 7alpha-[9-(4, 4, 5, 5, 5-pentafluoropentylsulfinyl)-nonyl]estra-1, 3, 5, (10)-triene-3, 17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res, 61, 6739-46.
5 Robertson JF, Llombart-Cussac A, Rolski J, et al (2009). Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol, 27, 4530-5.   DOI   ScienceOn
6 Valachis A, Mauri D, Polyzos NP, et al (2010). Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol, 73, 220-7.   DOI
7 Winer EP, Hudis C, Burstein HJ, et al (2005). American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol, 23, 619-29.
8 Xu B, Jiang Z, Shao Z, et al (2011). Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. Cancer Chemother Pharmacol 67, 223-30.   DOI
9 Jia WJ, Jia HX, Feng HY, et al (2014). HER2-enriched tumors have the highest risk of local recurrence in chinese patients treated with breast conservation therapy. Asian Pac J Cancer Prev, 15, 315-20.   과학기술학회마을   DOI   ScienceOn
10 Higgins JPT GS (2009). The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2.
11 Howell A, Robertson JF, Quaresma Albano J, et al (2002). Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol, 20, 3396-403.   DOI   ScienceOn
12 Howell A, Sapunar F (2011). Fulvestrant revisited: efficacy and safety of the 500-mg dose. Clin Breast Cancer, 11, 204-10.   DOI
13 Kuter I, Gee JM, Hegg R, et al (2012). Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. Breast Cancer Res Treat, 133, 237-46.   DOI
14 Mehta RS, Barlow WE, Albain KS, et al (2012). Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med, 367, 435-44.   DOI
15 Motamedi S, Majidzadeh K, Mazaheri M, Anbiaie R, Mortazavizadeh SM, Esmaeili R (2012). Tamoxifen resistance and CYP2D6 copy numbers in breast cancer patients. Asian Pac J Cancer Prev, 13, 6101-4.   과학기술학회마을   DOI
16 Najafi B, Anvari S, Roshan ZA (2013). Disease free survival among molecular subtypes of early stage breast cancer between 2001 and 2010 in Iran. Asian Pac J Cancer Prev, 14, 5811-16.   과학기술학회마을   DOI
17 Ohno S, Rai Y, Iwata H, et al (2010). Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol, 21, 2342-7.   DOI
18 Carlson RW, O'Neill A, Vidaurre T, et al (2012). A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat, 133, 1049-56.   DOI
19 Di Leo A, Jerusalem G, Petruzelka L, et al (2010). Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol, 28, 4594-600.   DOI
20 Bergh J, Jonsson PE, Lidbrink EK, et al (2012). FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 30, 1919-25.   DOI
21 Cope S, Ouwens MJ, Jansen JP, Schmid P (2013). Progression-Free Survival with Fulvestrant 500 mg and Alternative Endocrine Therapies as Second-Line Treatment for Advanced Breast Cancer: A Network Meta-Analysis with Parametric Survival Models. Value Health, 16, 403-17.   DOI
22 Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. Bmj, 315, 629-34.   DOI   ScienceOn
23 Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst, 90, 1371-88.   DOI   ScienceOn
24 Goldhirsch A, Wood WC, Coates AS, et al (2011). Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol, 22, 1736-47.   DOI   ScienceOn
25 Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.   DOI   ScienceOn
26 Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.   DOI   ScienceOn